ValueAct’s Valeant Problem

Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?


Michael Nagle


Michael Nagle

Photo credit: Bloomberg

By Michelle Celarier

ValueAct Capital Management’s Jeffrey Ubben has carefully cultivated a reputation as a good-guy activist who works with management to get results — a reputation that was built in part on his tremendous success with Canadian drugmaker Valeant Pharmaceuticals International.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.